Research & Regulatory News

What the Human Studies Have Found

UKPWritten and published by UK Peptides2 min readUpdated 4 cited sources

The short answer

Human evidence on thyroid cancer risk with GLP-1 receptor agonists includes a Scandinavian cohort study in the BMJ, an analysis of 13 obesity-associated cancers in JAMA Network Open, and a 2025 meta-analysis of randomised controlled trials.

Key facts

Pasternak 2024
BMJ, Scandinavian cohort (PMID 38683947)
Wang 2024
JAMA Netw Open, 13 cancers (PMID 38967919)
Silverii 2025
Diabetes Obes Metab, RCT meta-analysis (PMID 40437949)
Origin of concern
Rodent toxicology
Mechanistic context
Species difference in receptor expression
Boxed warning
Remains in place

Why cohort studies suit this question

Thyroid cancer is rare and develops over years. A randomised trial powered to detect a difference in its incidence would need to be impractically large and long. National registry cohorts provide the numbers and the follow-up that trials cannot, which is why the Scandinavian health registries are used for questions of this shape.

What the Scandinavian cohort offers

Pasternak and colleagues published on GLP-1 receptor agonist use and risk of thyroid cancer in the BMJ in April 2024. Scandinavian registries link prescribing, diagnoses and outcomes across whole populations with little loss to follow-up, which removes several biases that weaken cohort studies assembled from other sources.

Research material referenced

Retatrutide 10mg, third-party HPLC tested

Buy Retatrutide · £59.99

What a broader cancer analysis adds

Wang and colleagues examined GLP-1 receptor agonists and 13 obesity-associated cancers in patients with type 2 diabetes in JAMA Network Open in July 2024. Looking across many cancer types simultaneously puts any single finding in context. It also requires care, because examining thirteen outcomes raises the chance of one appearing notable by chance alone.

What a meta-analysis of trials contributes

Silverii and colleagues pooled randomised controlled trials in Diabetes, Obesity and Metabolism in 2025. Randomised data avoids confounding by indication, the problem that people prescribed a drug differ from those who are not. Its limitation is duration: pooling trials of a few years cannot address a cancer latency measured in decades.

Why the designs are complementary rather than competing

Trials are randomised but short. Cohorts are long but observational. Neither alone settles a rare, slow-developing outcome, and agreement between designs with different weaknesses is worth more than any single result. That convergence is the strongest form the evidence here can currently take.

How this sits against the warning

The boxed warning derives from rodent toxicology, and Waser and colleagues showed the receptor is not detected in normal human thyroid, a mechanistic reason the rodent finding might not extend. Human studies to date have not produced the signal the rodent data raised. That does not constitute demonstrated absence of risk, and the warning remains on the labels.

What this does not concern

Research material. Every study described here examines licensed medicines prescribed and monitored clinically. Nothing supplied on this site is a GLP-1 receptor agonist or is described by any of this evidence.

Frequently asked questions

Have human studies found increased thyroid cancer?

The cohort and randomised evidence described has not produced the signal the rodent toxicology raised. That is not the same as demonstrated absence of risk.

Why use registry cohorts rather than trials?

Thyroid cancer is rare and slow to develop. A trial powered to detect a difference in its incidence would be impractically large and long.

Has the boxed warning been removed?

No. It remains in place, and removing labelling requires a positive regulatory case rather than accumulating null findings.

Continue researching

Related guides and reference material.

Primary sources & clinical trials

Published papers, trial registrations, regulator pages and company announcements. Links open the original.

UKP

Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).

Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.

Corrections log

More Research & Regulatory News articles

Research use only. The information above is provided for scientific and educational reference. Compounds referenced are not approved for human use and are supplied for in vitro research or reference-material purposes only. No efficacy, safety, or therapeutic claims are made.